Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Link Between Agent Orange, Cancer Confirmed

May 1, 1996
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 5
Volume 5
Issue 5

WASHINGTON--In an update of its 1994 report, the Institute of Medicine (IOM), of the National Academy of Sciences, has confirmed its original findings of an association between herbicides used in the Vietnam War and various health problems, namely, soft tissue sarcoma, non-Hodgkin's lymphoma, Hodgkin's disease, and chloracne.

WASHINGTON--In an update of its 1994 report, the Institute ofMedicine (IOM), of the National Academy of Sciences, has confirmedits original findings of an association between herbicides usedin the Vietnam War and various health problems, namely, soft tissuesarcoma, non-Hodgkin's lymphoma, Hodgkin's disease, and chloracne.

The update also reported limited or suggestive epidemiologicalevidence for three newly discovered associations: a higher rateof spina bifida in children born to Vietnam vets, compared withnon-vets, and a higher incidence of transient peripheral neuropathyand por-phyria cutanea tarda in people exposed to herbicides ordioxin.

Between 1962 and 1970, US soldiers sprayed almost 20 million gallonsof Agent Orange and other defoliants over 3.6 million acres inVietnam. After studies linked Agent Orange to birth defects inlaboratory animals, the use of the chemical was suspended.

IOM committee chair David Tollerud, director of occupational andenvironmental medicine, University of Pittsburgh, said that "westill do not know the precise degree of risk from Agent Orangeexposure for individual Vietnam vet-erans, but the base of researchhas improved."

Articles in this issue

No Need to Delay Mammography After FNA, Study Shows
Pediatric Cancer Guidelines Are a National Effort
EPA Proposes Changes in Determining Cancer Risk of Chemicals, Pollutants
ATL's HDI Digital Ultrasound Is Approved for Breast Indication
Cell-Adhesion Molecules May Be Key to Controlling Metastases in Breast Cancer
NIH Study Suggests That 200 mg Is The Optimal Daily Dose of Vitamin C
Natural History of HIV Supports the Use Of Early Interventions
Aids Vaccine Trial Fails to Show Clinical Benefit
Rep. Porter Honored For Work on Budget
Forum Airs Issue of Who Should Pay for Patient Care in Cancer Clinical Trials
Blenoxane Cleared for New Use In Malignant Pleural Effusion
Implementation of Critical Path Reduces Prostatectomy Costs
Berlex Foundation Seeks Workshop Applicants
Networking Venture Benefits Both
Health of Biotech Industry a Concern to Oncologists
Recent Videos
Greater direct access to academic oncologists may help address challenges associated with a lack of CAR T education in the community setting.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
Accelerated approval of afami-cel may expand access to therapy for patients who are unable to live near certain treatment centers.
Treatment with afami-cel may offer improved quality of life to patients with metastatic synovial sarcoma compared with continuous chemotherapy.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Related Content
Advertisement

Findings support the established safety profile of lisocabtagene maraleucel across hematologic oncology indications.

Data Show Low Severity AEs With Liso-Cel Across Blood Cancer Settings

Russ Conroy
June 1st 2025
Article

Findings support the established safety profile of lisocabtagene maraleucel across hematologic oncology indications.


Therapies like betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD
May 5th 2025
Podcast

Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.


The FDA designation follows an orphan drug designation granted by the European Medicines Agency for THE001 in patients with soft tissue sarcoma.

FDA Grants THE001 Orphan Drug Designation for Soft Tissue Sarcomas

Roman Fabbricatore
May 12th 2025
Article

The FDA designation follows an orphan drug designation granted by the European Medicines Agency for THE001 in patients with soft tissue sarcoma.


A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Leveraging Ex Vivo Gene Therapy Advancements in Hemoglobinopathies and Metabolic Diseases

Alexis K. Kuhn, PharmD, BCOP ;Katie Bruce, PharmD, BCPPS;Susie Long, PharmD
October 21st 2024
Podcast

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.


Based on FDA feedback, the developers plan to discontinue the phase 3 EQUATOR study, which evaluated itolizumab in acute graft-versus-host disease.

FDA Rejects Breakthrough Designation, Approval for Itolizumab in Acute GVHD

Roman Fabbricatore
April 25th 2025
Article

Based on FDA feedback, the developers plan to discontinue the phase 3 EQUATOR study, which evaluated itolizumab in acute graft-versus-host disease.


Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies

Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies

American Society for Transplantation and Cellular Therapy
April 24th 2025
Article

Researchers conducted a comprehensive review on how intrinsic T cell characteristics influence CAR-T cell therapy outcomes in hematological malignancies.

Related Content
Advertisement

Findings support the established safety profile of lisocabtagene maraleucel across hematologic oncology indications.

Data Show Low Severity AEs With Liso-Cel Across Blood Cancer Settings

Russ Conroy
June 1st 2025
Article

Findings support the established safety profile of lisocabtagene maraleucel across hematologic oncology indications.


Therapies like betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD
May 5th 2025
Podcast

Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.


The FDA designation follows an orphan drug designation granted by the European Medicines Agency for THE001 in patients with soft tissue sarcoma.

FDA Grants THE001 Orphan Drug Designation for Soft Tissue Sarcomas

Roman Fabbricatore
May 12th 2025
Article

The FDA designation follows an orphan drug designation granted by the European Medicines Agency for THE001 in patients with soft tissue sarcoma.


A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Leveraging Ex Vivo Gene Therapy Advancements in Hemoglobinopathies and Metabolic Diseases

Alexis K. Kuhn, PharmD, BCOP ;Katie Bruce, PharmD, BCPPS;Susie Long, PharmD
October 21st 2024
Podcast

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.


Based on FDA feedback, the developers plan to discontinue the phase 3 EQUATOR study, which evaluated itolizumab in acute graft-versus-host disease.

FDA Rejects Breakthrough Designation, Approval for Itolizumab in Acute GVHD

Roman Fabbricatore
April 25th 2025
Article

Based on FDA feedback, the developers plan to discontinue the phase 3 EQUATOR study, which evaluated itolizumab in acute graft-versus-host disease.


Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies

Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies

American Society for Transplantation and Cellular Therapy
April 24th 2025
Article

Researchers conducted a comprehensive review on how intrinsic T cell characteristics influence CAR-T cell therapy outcomes in hematological malignancies.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.